Marinus Pharmaceuticals, Inc. (MRNS) News

Marinus Pharmaceuticals, Inc. (MRNS): $1.33

0.03 (+2.31%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add MRNS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#258 of 362

in industry

Filter MRNS News Items

MRNS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRNS News Highlights

  • MRNS's 30 day story count now stands at 2.
  • Over the past 17 days, the trend for MRNS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AES are the most mentioned tickers in articles about MRNS.

Latest MRNS News From Around the Web

Below are the latest news stories about MARINUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MRNS as an investment opportunity.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa., December 07, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 74,650 shares of its common stock (the "Common Stock") and the grant of restricted stock units which,

Yahoo | December 7, 2023

Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study

RADNOR, Pa., November 20, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the acceptance of seven abstracts for presentation at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting, taking place in Orlando, Florida December 1-5, 2023. Marinus will also host a scientific exhibit showcasing a series of posters highlighting the potential of ganaxolone in the t

Yahoo | November 20, 2023

Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference

RADNOR, Pa., November 14, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference.

Yahoo | November 14, 2023

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript November 7, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.67. Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]. And now, it is my pleasure to introduce your host, Sonya […]

Yahoo | November 8, 2023

Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results

Company sees strong quarter over quarter growth and robust payer coverage for ZTALMY

Yahoo | November 7, 2023

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

RADNOR, Pa., November 07, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Yahoo | November 7, 2023

Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV

RADNOR, Pa., November 07, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY® (ganaxolone) oral suspension CV. The new program enables physicians to request ZTALMY for eligible patients with seizures associated with CDKL5 deficiency disorder (CDD) in geographies where the product is n

Yahoo | November 7, 2023

Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023

RADNOR, Pa., October 24, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023.

Yahoo | October 24, 2023

Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 183.3% in Marinus Pharmaceuticals (MRNS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | October 11, 2023

Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

RADNOR, Pa., September 21, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference.

Yahoo | September 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!